Celldex Therapeutics, Inc (CLDX) Financials
Key financial figures for Celldex Therapeutics, Inc (Q3 2026).
Celldex ended Q3 2026 with $650.3 million in cash and marketable securities, which it says funds planned operations through 2028, after reporting best-in-disease Phase 3 CSU results in September and guiding to a 2027 BLA submission. Net loss was $75.6 million, or $0.96 per share, for the third quarter of 2026, versus $67.0 million, or $1.01 per share, a year earlier. The release carried no revenue for the quarter and no analyst estimate is cited here, so there is no beat or miss call. Research and development expense was $67.4 million, up from $62.9 million in Q3 2025, on barzolvolimab clinical trial and contract manufacturing expense and higher headcount. General and administrative expense was $14.8 million, up from $10.7 million, on barzolvolimab commercial planning and headcount. On the outlook: Celldex believes that cash, cash equivalents and marketable securities at September 30, 2026 ($650.3 million) are sufficient to meet estimated working capital requirements and fund current planned operations through 2028; BLA submission for barzolvolimab in CSU anticipated in 2027. Figures are for Q3 2026, as Celldex Therapeutics reported them.
- Revenue
- $0
- Net Income
- -$76M
- EPS
- $-0.96
- Total Assets
- $722M
- Operating Cash Flow
- -$65M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $0 | -$76M | -$0.96 | -$67M | |
| Q2 FY2026 | $22K | -$74M | -$0.94 | -366468.18% | -$61M |
| Q1 FY2026 | $15K | -$79M | -$1.18 | -562900% | -$67M |
| Q4 FY2025 | $75K | -$81M | -$1.23 | -116249.33% | -$65M |
| Q3 FY2025 | $0 | -$67M | -$1.01 | -$49M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $2M | -$259M | -$3.90 | -19160% | -$214M |
| FY2024 | $7M | -$158M | -$2.45 | -2778.89% | -$160M |
| FY2023 | $7M | -$141M | -$2.92 | -2245.27% | -$109M |
Frequently asked questions
What was Celldex Therapeutics's revenue last quarter?
Celldex Therapeutics reported revenue of $0.00 for Q3 FY2026.
Is Celldex Therapeutics profitable?
Not in its most recent reported period. Celldex Therapeutics reported a net loss of $75.6 million for Q3 FY2026.
How much free cash flow did Celldex Therapeutics generate?
Celldex Therapeutics generated free cash flow of -$66.7 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Celldex Therapeutics, Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.